A Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2033-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dosage of ibrutinib when
administered in combination with rituximab in participants with relapsed or refractory (r/r)
mantle cell lymphoma (MCL) (Phase 2); and to compare the progression-free survival (PFS) of
ibrutinib plus rituximab versus physician's choice of lenalidomide plus rituximab or
bortezomib plus rituximab (Phase 3).